Evidence map›Paper›PMID 42607890›Full record

ArticleThe Journal of biological chemistry2026

The crystal structure of the activin B:Fst288 complex and computational insights into the broad antagonistic activity and specificity of follistatin.

Lucija Hok, Ryan G Walker, James A Howard, Melissa M Gouge, Eleanor M Mast, Chandramohan Kattamuri, Erich J Goebel, Thomas B Thompson

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Lucija HokDepartment of Molecular & Cellular Biosciences, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Ryan G WalkerDepartment of Molecular & Cellular Biosciences, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
James A HowardDepartment of Pharmacology & Systems Physiology, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Melissa M GougeDepartment of Molecular & Cellular Biosciences, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Eleanor M MastDepartment of Molecular & Cellular Biosciences, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Chandramohan KattamuriDepartment of Molecular & Cellular Biosciences, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Erich J GoebelDepartment of Molecular & Cellular Biosciences, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Thomas B ThompsonDepartment of Molecular & Cellular Biosciences, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA. Electronic address: Tom.Thompson@uc.edu.

Funding

Structural/functional characterization of TGFβ superfamily signaling and regulationR35GM134923 · NIGMS · UNIVERSITY OF CINCINNATI · PI THOMPSON, THOMAS B · 2020 to 2024
$2.6M
NIGMS NIH HHS R35 GM134923
6 · The paper itself

Abstract

Members of the transforming growth factor-β (TGF-β) family regulate essential biological processes, and their activity is tightly controlled by extracellular antagonists like follistatin 288 (Fst288). While Fst288 potently inhibits several ligands, including activins A and B, GDF8, and GDF11, the structural basis for its interaction with activin B (ActB) has remained largely uncharacterized. This lack of data has limited our understanding of how Fst288 achieves such broad inhibitory activity while maintaining ligand-specific selectivity. In this study, we resolved the crystal structure of the ActB:Fst288 complex at 2.7 Å resolution. Our findings reveal that while Fst288 utilizes a conserved receptor-blocking mechanism, ActB engages the antagonist through a modified structural mode. Most notably, the fingertips of ActB form direct, unique contacts with the third follistatin domain (FSD3). This interaction disrupts the intermolecular head-to-tail cooperativity typically seen in Fst288 dimers, shifting the stabilization of the complex toward individual ligand-domain affinities. Computational analysis supports a model where ActB relies more on direct contacts with Fst288, whereas ActA relies on the intermolecular head-to-tail Fst288 interactions. Further computational analysis indicates ActB is more flexible than ActA and GDF8. These results suggest that Fst288's broad potency arises from a dynamic interplay between ligand flexibility and antagonist conformational plasticity that can accommodate different ligand surfaces. By elucidating unique characteristics of the ActB:Fst288 interface, this study deepens the understanding of ligand selectivity and provides a framework for the rational design of targeted TGF-β antagonists.

Indexed as

activin B (ActB)follistatin 288 (Fst288)molecular dynamics simulations (MDS)transforming growth factor beta family (TGF-β)X-ray crystallography

Identifiers

PMID42607890
PMCPMC13590098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.